{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:23Z","timestamp":1761512903166},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1827,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/jto.0b013e3181fd42eb","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T11:53:39Z","timestamp":1290513219000},"page":"1963-1969","source":"Crossref","is-referenced-by-count":28,"title":["Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB\/IV Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"Mark A.","family":"Socinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Raju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren M.","family":"Kocs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Rousey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janak K.","family":"Choksi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra A.","family":"Patt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip O.","family":"Periman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard R.","family":"Schlossberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Bromund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Treat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coleman K.","family":"Obasaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181fd42eb_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00001622-199303000-00010","article-title":"Screening, diagnosis, and staging of lung cancer","volume":"5","author":"Shepherd","year":"1993","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0954-6111(05)80061-7","article-title":"Chemotherapy for advanced non-small-cell lung cancer","volume":"88","author":"Walling","year":"1994","journal-title":"Respir Med"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib4","author":"NCCN"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib5","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.1993.11.10.1866","article-title":"Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?","volume":"11","author":"Grilli","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.106.3.861","article-title":"Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature","volume":"106","author":"Marino","year":"1994","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0140-6736(93)91882-M","article-title":"Polychemotherapy in advanced non small cell lung cancer: a meta-analysis","volume":"342","author":"Souquet","year":"1993","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(02)00526-3","article-title":"Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study","volume":"40","author":"Kortsik","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib9","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO.2002.12.112","article-title":"Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial","volume":"20","author":"Kosmidis","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib10","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib12","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib13","first-page":"381","article-title":"Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells","volume":"8","author":"Barr","year":"1997","journal-title":"Cell Growth Differ"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib14","first-page":"780","article-title":"Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance","volume":"63","author":"Clark","year":"2003","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2559.2006.02461.x","article-title":"Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer","volume":"49","author":"Lahn","year":"2006","journal-title":"Histopathology"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","article-title":"Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis","volume":"51","author":"Tang","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib17","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/annonc\/mdp049","article-title":"Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced\/metastatic cancer","volume":"20","author":"Hanauske","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.2007.14.3685","article-title":"Enzastaurin, an oral serine\/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer","volume":"26","author":"Oh","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CCO.0b013e328322ca04","article-title":"Histology-based treatment: a new scenario in the management of advanced nonsmall cell lung cancer","volume":"21","author":"Gridelli","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2009.04.023","article-title":"Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT)","volume":"67","author":"Gridelli","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib21","first-page":"1042","article-title":"The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review","volume":"4","author":"Hirsch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib22","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib23","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/cncr.21480","article-title":"Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer","volume":"104","author":"Zinner","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.690.11.2","article-title":"Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial","volume":"11","author":"Scagliotti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib25","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib26","series-title":"American Joint Committee on Cancer Staging Manual","author":"Fleming","year":"1998"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib29","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE), Cancer Therapy Evaluation Program, 2003."},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-5002(95)00450-F","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument","volume":"12","author":"Cella","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e19050","article-title":"A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) \u00b1 enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)","author":"Raju","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib34","unstructured":"von Pawel J, Barlesi F, Soria J, et al. A phase II, double-blind, randomized study of enzastaurin versus placebo concurrently with pemetrexed as second-line therapy in patients with advanced or metastatic non-small cell lung cancer. 13th World Conference on Lung Cancer, 2009: D2.7 (abstract)."},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib35","author":"Casey","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib36","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"Gr\u00f8nberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib37","unstructured":"Chansky K, Mack P, Crowley J, et al. Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule (AMT)-platinum therapy. 13th World Conference on Lung Cancer, 2009: B2.7 (abstract)."},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib38","unstructured":"Hoang T, Dahlberg S, Schiller J, et al. Does histology predict survival of advanced non-small cell lung cancer (NSCLC) treated with standard platin-based chemotherapy? Retrospective analysis of E1594. 13th World Conference on Lung Cancer, 2009: PD6.4.1 (abstract)."},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.18_suppl.cra8000","article-title":"Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC)","author":"Belani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib41","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3816\/CLC.2009.n.035","volume":"10","author":"Patel","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181fd42eb_bib43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3816\/CLC.2010.n.045","volume":"11","author":"Zinner","year":"2010","journal-title":"Clin Lung Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415318694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415318694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T08:05:45Z","timestamp":1685865945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415318694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1556086415318694"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181fd42eb","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}